Mabwell Shanghai Bioscience (SHA:688062) said its novel monoclonal antibody 9MW1911 demonstrated strong efficacy signals in reducing exacerbations in patients with moderate-to-severe chronic obstructive pulmonary disease, according to a weekend filing with the Shanghai bourse.
In the Ib/IIa trial of 80 former-smoking patients, annualized rates of moderate-to-severe attacks dropped by 24% and 81% at 600-milligram and 900-mg doses versus placebo, while severe exacerbation rates fell by 47% and 100%, respectively.
Shares of the pharmaceutical company were down 1% in recent trade.